BioSpace News Archive

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced positive topline results from its Phase 3 pivotal RESPONSE study.

DURECT Corporation today announced that the last patient has completed the study protocol in the Company’s AHFIRM trial.

Avantor, Inc. has entered into an agreement with Tobin Scientific, a leading provider of biopharma cold chain, ambient storage, and transport & logistics services, to support end-to-end moves for biopharma customers looking to relocate their labs, research facilities, and samples.

Aeglea BioTherapeutics, Inc. today announced it will effect a reverse stock split of all outstanding shares of Aeglea’s common stock at a ratio of 1-for-25. Aeglea expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on September 8, 2023.

PDO MAX, Inc., a woman-owned aesthetics medical device company based in the United States, introduces its third innovation for 2023. Shaping up to be the most exciting year in the company’s history, our latest offering is the Glowpin serum infusion system, which combines a multi-needle stimulator with an airless pump.

Ocuphire Pharma, Inc. today announced that it will present clinical data on APX3330 and Nyxol ® at the 41st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) to take place September 8th - 11th, in Vienna, Austria.

Eminence Biotechnology Co., Ltd. is delighted to announce that its state-of-the-art facility for the commercial production of cell culture media is now fully operational.

PacBio today announced that automation providers Hamilton, Integra, Revvity and Tecan have created fully automated protocols to prepare samples for sequencing on Revio and Sequel II and IIe systems.

Daxor Corporation announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11 - 13, 2023 at the Lotte New York Palace.

Nature’s Toolbox, Inc. (NTx) today announced it has been awarded a contract under the Vaccines on Demand program from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.